Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2015, Article ID 891582, 6 pages
http://dx.doi.org/10.1155/2015/891582
Clinical Study

Twelve-Year Outcomes of Pterygium Excision with Conjunctival Autograft versus Intraoperative Mitomycin C in Double-Head Pterygium Surgery

1Hong Kong Eye Hospital, 147K Argyle Street, Kowloon, Hong Kong
2Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong
3Department of Ophthalmology, The University of Hong Kong, Hong Kong

Received 1 January 2015; Accepted 19 February 2015

Academic Editor: Bartosz Sikorski

Copyright © 2015 Tommy C. Y. Chan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. The study aims to compare the long-term outcome of conjunctival autograft (CAU) and mitomycin C (MMC) in double-head pterygium surgery. Methods. This is a follow-up study of a comparative interventional trial. Thirty-nine eyes of the 36 patients with double-head pterygium excision in the original study 12 years ago were recruited for clinical assessment. Seven out of the 36 patients were lost. In the original study, each eye with double-head pterygium was randomized to have pterygium excision with CAU on one “head” (temporal or nasal) and MMC on the other “head.” All patients were invited for clinical assessment for conjunctival bed status and the presence of pterygium recurrence in the current study. Results. There was no significant difference between the size, morphology, and type of pterygium among the two treatment groups. The recurrence rate of CAU group and MMC group 12 years after excision was 6.3% and 28.1%, respectively (). Among eyes without recurrence, the conjunctival bed was graded higher in the MMC group than the CAU group (). Conclusion. The use of conjunctival autograft has a significantly lower long-term recurrence rate than mitomycin C in double-head pterygium surgery.